Exelixis Inc (EXEL)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$69.39

Buy

$72.49

arrow-up$3.19 (+4.82%)

Prices updated at 30 Oct 2026, 23:51 EDT
| Prices minimum 15 mins delay
|
Prices in USD
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and fo ...
NASDAQ
arrow-down-2.86%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Stelios Papadopoulos,PhD
CEO
Dr. Michael M. Morrissey, PhD
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
1,077
Head office
1851 Harbor Bay Parkway
Alameda
United States
94502
mobile
+1 650 837-7000
letter
shubbard@exelixis.com
computer
Company website

Key personnel

Owner name
chevron-l-regular
chevron-r-regular
Salary
Dr. George H. Poste, D.V.M.,F.R.S.,PhD
Independent Director
0.10m
Mr. Jack L. Wyszomierski, M.S.
Independent Director
0.10m
Dr. Michael M. Morrissey, PhD
Director, President and Chief Executive Officer
1.31m
Dr. Stelios Papadopoulos,PhD
Chairman of the Board
0.14m
Mr. David E. Johnson
Independent Director
0.09m
Dr. Mary C. Beckerle, PhD
Independent Director
0.09m
Dr. Maria C. Freire, PhD
Independent Director
0.10m
Ms. Julie Anne Smith
Independent Director
0.10m
Mr. Christopher J. Senner
Executive Vice President, Chief Financial Officer and Principal Accounting Officer
0.82m
Mr. Patrick J. Haley
Executive Vice President, Commercial
0.62m
Mr. Tomas J. Heyman
Independent Director
0.10m
Dr. Sue Gail Eckhardt, M.D.
Independent Director
0.08m
Dr. Dana T. Aftab, PhD
Executive Vice President, Research and Development
0.66m
Mr. Robert Oliver, M.B.A.
Independent Director
0.08m
Dr. Brenda Hefti, J.D.,PhD
Senior Vice President and General Counsel
0.45m

Top 5 shareholders

Owner name
chevron-l-regular
chevron-r-regular
No. of shares
BlackRock Inc30,816,309
BlackRock Fund Advisors16,434,890
Vanguard Group Inc14,695,085
Renaissance Technologies Corp13,726,993
Farallon Capital Management, L.L.C.13,111,010

Director dealings

Date
chevron-l-regular
chevron-r-regular
Action
03 Dec 2025-
21 Nov 2025-
21 Nov 2025-
20 Nov 2025-
20 Nov 2025-
20 Nov 2025-
17 Nov 2025-
12 Nov 2025-
12 Nov 2025-
11 Nov 2025-
12 Nov 2025-
12 Nov 2025-
11 Nov 2025-
11 Nov 2025-
11 Nov 2025-
11 Nov 2025-
11 Nov 2025-
08 Oct 2025-
03 Jun 2025-
02 Jun 2025-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser.

© Copyright 2026 Morningstar. All rights reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

The ESG-related information, methodologies, tools, ratings, data and opinions contained or reflected herein are not directed to or intended for use or distribution to India-based clients or users and their distribution to Indian resident individuals or entities is not permitted, and Morningstar accepts no responsibility or liability whatsoever for the actions of third parties in this respect.